2 results about "Candida dubliniensis" patented technology

Disclosed herein are methods of treating or preventing a metabolic disease in a subject. The methods include administering to the subject a composition comprising Candida dubliniensis in an amount effective to treat or prevent or reduce a metabolic disease. Methods of treating diabetes or promoting or enhancing proliferation of beta cell development or beta cell regeneration are also provided.

The application discloses a primer probe combination, a kit and application for detecting pathogenic microorganisms in a genital tract, wherein the primer probe combination comprises primer probe sequences shown in SEQ ID NO. 1-SEQ ID NO. 96, the pathogenic microorganisms in the genital tract include 27 pathogenic microorganisms which can cause diseases in the genital tract, such as Ureaplasma parvum, Ureaplasma urealyticum, Mycoplasma hominis, Mycoplasma genitalium, Candida albicans, Candida glabrata, Candida tropicalis, Candida auris, Candida krusei, Candida dubliniensis and the like, and four common vaginal lactobacilli, such as Lactobacillus crispatus, Lactobacillus jensenii, Lactobacillus gasseri and Lactobacillus iners, and further include a human internal standard. Based on the fluorescence quantitative PCR technology, the 27 pathogenic microorganisms which can cause diseases in the genital tract and the four common vaginal lactobacilli can be simultaneously detected in an in-vitro sample, the main pathogenic microorganisms of the genital tract infection can be covered, the evaluation of the vaginal ecological environment can be satisfied, the detection time is shortened to about 40 minutes, and the specificity and the sensitivity are good.